Protagenic Therapeutics, Inc.\new annual operating income
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Protagenic Therapeutics, Inc.\new Operating Income Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's operating income was −$4.5M for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | −$4.5M | −$1.9M | — |
| 2025 | 2025-03-31 | −$2.6M | — | — |
| 2024 | 2024-12-31 | −$5.7M | −$1.2M | — |
| 2023 | 2023-12-31 | −$4.5M | −$969,186 | — |
| 2022 | 2022-12-31 | −$3.6M | $582,625 | — |
| 2021 | 2021-12-31 | −$4.1M | −$1.6M | — |
| 2020 | 2020-12-31 | −$2.6M | −$465,481 | — |
| 2019 | 2019-12-31 | −$2.1M | $227,997 | — |
| 2018 | 2018-12-31 | −$2.3M | $51,197 | — |
| 2017 | 2017-12-31 | −$2.4M | −$131,823 | — |
| 2016 | 2016-12-31 | −$2.2M | −$1.2M | — |
| 2015 · Dec 31 | 2015-12-31 | −$1.0M | — | — |
| 2015 · Jun 30 | 2015-06-30 | −$491,000 | $484,000 | — |
| 2014 | 2014-06-30 | −$975,000 | — | — |
Protagenic Therapeutics, Inc.\new quarterly operating income
Q2.11
Q3.11
Q2.11
Q3.11
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | −$961,247 | $247,127 | — |
| Q4 2026 | 2026-03-31 | −$1.3M | $191,739 | — |
| Q3 2026 | 2025-12-31 | −$925,103 | −$523,702 | — |
| Q2 2026 | 2025-09-30 | −$1.1M | −$758,490 | — |
| Q1 2026 | 2025-06-30 | −$1.2M | −$886,543 | — |
| Q4 2025 | 2025-03-31 | −$1.4M | $290,251 | — |
| Q4 2024 | 2024-12-31 | −$401,401 | $810,825 | — |
| Q3 2024 | 2024-09-30 | −$355,374 | $1.1M | — |
| Q2 2024 | 2024-06-30 | −$321,831 | $821,911 | — |
| Q1 2024 | 2024-03-31 | −$1.7M | −$999,065 | — |
| Q4 2023 | 2023-12-31 | −$1.2M | −$556,448 | — |
| Q3 2023 | 2023-09-30 | −$1.4M | −$507,652 | — |
| Q2 2023 | 2023-06-30 | −$1.1M | −$507,068 | — |
| Q1 2023 | 2023-03-31 | −$739,294 | $601,982 | — |
| Q4 2022 | 2022-12-31 | −$655,778 | $205,441 | — |
| Q3 2022 | 2022-09-30 | −$924,060 | −$159,889 | — |
| Q2 2022 | 2022-06-30 | −$636,674 | $672,159 | — |
| Q1 2022 | 2022-03-31 | −$1.3M | −$135,086 | — |
| Q4 2021 | 2021-12-31 | −$861,219 | −$411,303 | — |
| Q3 2021 | 2021-09-30 | −$764,171 | $327,845 | — |
| Q2 2021 | 2021-06-30 | −$1.3M | −$819,890 | — |
| Q1 2021 | 2021-03-31 | −$1.2M | −$685,454 | — |
| Q4 2020 | 2020-12-31 | −$449,916 | $287,313 | — |
| Q3 2020 | 2020-09-30 | −$1.1M | −$902,394 | — |
| Q2 2020 | 2020-06-30 | −$488,943 | $16,321 | — |
| Q1 2020 | 2020-03-31 | −$520,736 | $133,279 | — |
| Q4 2019 | 2019-12-31 | −$737,229 | −$212,981 | — |
| Q3 2019 | 2019-09-30 | −$189,622 | $308,448 | — |
| Q2 2019 | 2019-06-30 | −$505,264 | $179,861 | — |
| Q1 2019 | 2019-03-31 | −$654,015 | −$47,331 | — |
| Q4 2018 | 2018-12-31 | −$524,248 | $184,535 | — |
| Q3 2018 | 2018-09-30 | −$498,070 | $28,962 | — |
| Q2 2018 | 2018-06-30 | −$685,125 | −$213,536 | — |
| Q1 2018 | 2018-03-31 | −$606,684 | $51,236 | — |
| Q4 2017 | 2017-12-31 | −$708,783 | −$152,507 | — |
| Q3 2017 | 2017-09-30 | −$527,032 | −$72,205 | — |
| Q2 2017 | 2017-06-30 | −$471,589 | $25,067 | — |
| Q1 2017 | 2017-03-31 | −$657,920 | $67,822 | — |
| Q4 2016 | 2016-12-31 | −$556,276 | −$405,276 | — |
| Q3 2016 | 2016-09-30 | −$454,827 | −$93,988 | — |
| Q2 2016 | 2016-06-30 | −$496,656 | −$395,693 | — |
| Q1 2016 · Mar 31 | 2016-03-31 | −$725,742 | −$675,821 | — |
| Q4 2015 | 2015-12-31 | −$151,000 | −$14,000 | — |
| Q1 2016 · Sep 30 | 2015-09-30 | −$360,839 | −$242,839 | — |
| Q4 2015 · Jun 30 | 2015-06-30 | −$100,963 | $28,037 | — |
| Q3 2015 | 2015-03-31 | −$49,921 | $348,079 | — |
| Q2 2015 | 2014-12-31 | −$137,000 | $105,000 | — |
| Q1 2015 | 2014-09-30 | −$118,000 | $88,000 | — |
| Q4 2014 | 2014-06-30 | −$129,000 | — | — |
| Q3 2014 | 2014-03-31 | −$398,000 | — | — |
| Q2 2014 | 2013-12-31 | −$242,000 | — | — |
| Q1 2014 | 2013-09-30 | −$206,000 | — | — |
| Q3 2011 · Sep 30 | 2011-09-30 | −$5.0M | −$1.4M | — |
| Q2 2011 · Jun 30 | 2011-06-30 | −$5.0M | −$535,000 | — |
| Q3 2011 · Sep 30 | 2010-09-30 | −$3.7M | — | — |
| Q2 2011 · Jun 30 | 2010-06-30 | −$4.5M | — | — |
Protagenic Therapeutics, Inc.\new operating income trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's operating income decreased from −$975,000 to −$4.5M, a change of −$3.5M. The latest reported quarter, Q1 2027, shows −$961,247.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗